The Exchange has sought clarification from Dishman Pharmaceuticals and Chemicals with reference to the news reported on moneycontrol on 17/11/2015 - ‘USFDA gives Warning Letter to Dishman due to Clovis issues’.
The above information is a part of company’s filings submitted to BSE.